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Human herpesvirus-6 (HHV-6) is known to reactivate after allogeneic hematopoietic stem cell transplantation
(allo-HSCT) and may be associated with development of acute graft-versus-host disease (GVHD) and non-
relapse mortality (NRM). However, the clinical signiﬁcance of HHV-6 reactivation after allo-HSCT remains
unclear. Therefore, we conducted a retrospective analysis to elucidate the impact of HHV-6 reactivation on
transplantation outcomes. Of 236 patients who underwent allo-HSCT, 138 (58.5%) developed HHV-6 reac-
tivation and 98 (41.5%) did not. Univariate analysis indicated that at 3 years, patients with HHV-6 reactivation
had signiﬁcantly higher NRM (27.7% versus 13.7%, P¼ .003) and worse overall survival (42.1% versus 59.0%, P¼
.008) than those without reactivation. In multivariate analysis, HHV-6 reactivation was associated with higher
incidence of acute GVHD (hazard ratio [HR], 1.87; P ¼ .01), cytomegalovirus reactivation (HR, 2.24; P < .001),
and NRM (HR, 2.73; P ¼ .007). Subgroup analysis stratiﬁed according to conditioning intensity indicated that a
signiﬁcant impact of HHV-6 reactivation on acute GVHD was observed only in patients who received mye-
loablative conditioning (MAC). These results indicate that HHV-6 reactivation was associated with develop-
ment of acute GVHD, cytomegalovirus reactivation, and NRM. Furthermore, adverse impact of HHV-6
reactivation on transplantation outcomes was prominent in the setting of MAC.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION Therefore, we conducted a single-center study of 236
Human herpesvirus-6 (HHV-6) ubiquitously infects
healthy individuals during early childhood [1]. Primary HHV-
6 infection causes exanthema subitum and acute febrile
illness [2]. Like other herpes viruses, HHV-6 establishes a
latent infection after the primary infection [3]. The latent
infection can reactivate during severe immunosuppression,
such as that induced under allogeneic hematopoietic stem
cell transplantation (allo-HSCT). Previous studies revealed
that HHV-6 reactivates in approximately one half of patients
after allo-HSCT and reactivation causes skin rash [4-7], fever,
and encephalitis [8-14]. HHV-6 reactivation also has been
associatedwith poor outcomes, including acute graft-versus-
host disease (GVHD) [15-20], cytomegalovirus (CMV) reac-
tivation [6,7,15,16], delayed platelet recovery [9,15,19], and
increased mortality. However, the actual clinical signiﬁcance
of HHV-6 reactivation remains unclear.dgments on page 2021.
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ty for Blood and Marrow Transplantation.patients who underwent allo-HSCT in our hospital. The
purpose of the current study was to determine the clinical
impact of HHV-6 reactivation on early complications and
outcomes after allo-HSCT.
MATERIALS AND METHODS
Study Population
Clinical data were collected from the clinical records of Kanagawa
Cancer Center. Patients aged 16 years or older who underwent a ﬁrst allo-
HSCT between April 2004 and December 2013 were evaluated for anal-
ysis. Of 242 patients, HHV-6 monitoring was performed for 236 patients.
Plasma samples were collected weekly from 1 or 2 weeks until 4 weeks after
transplantation. HHV-6 DNA copy numbers were measured using real-time
polymerase chain reaction, as described previously [12]. Since 2008, fos-
carnet sodium 3 g/body was started when HHV-6 DNA exceeded 125 copies/
mL. We retrospectively analyzed the clinical impact of HHV-6 reactivation
on outcomes of allo-HSCT. This study was approved by the institutional
review board of the Kanagawa Cancer Center.
Statistical Analysis
HHV-6 reactivationwas deﬁned as a detection of HHV-6 DNA at any level.
CMV reactivation was deﬁned as more than 1 cell per 3.0  104 peripheral
blood mononuclear cells positive for CMV pp65 antigen.
A myeloablative conditioning (MAC) regimen was deﬁned as regimen
having the following dosage level: total body irradiation > 8 Gy, oral
Table 1
Patient Characteristics
Characteristic HHV-6 Reactivation P Value
No (n ¼ 98) Yes (n ¼ 138)
Age, median (range), yr 46 (17-65) 48 (18-67) .10
Sex
Male 61 (62.2%) 78 (56.5%)
Female 37 (37.8%) 60 (43.5%) .42
Disease
AML 59 (60.2%) 83 (60.1%)
ALL 57 (21.4%) 34 (24.6%)
Others 51 (18.4%) 21 (15.2%) .76
Disease risk
High 31 (31.6%) 60 (43.5%)
Low 67 (68.4%) 78 (56.5%) .08
Conditioning
MAC 61 (62.2%) 78 (56.5%)
RIC 37 (37.8%) 60 (43.5%) .42
Donor source
M-RD 50 (51.0%) 17 (12.3%)
MM-RD 3 (3.1%) 10 (7.2%)
WPM-URD 26 (26.5%) 35 (25.4%)
MM-URD 7 (7.1%) 24 (17.4%)
UR-CB 12 (12.2%) 52 (37.7%) <.001
AML indicates acute myeloid leukemia; ALL, acute lymphoblastic leukemia;
M-RD, matched related donor; MM-RD, mismatched related donor; WPM-
URD, well or partially matched unrelated donor; MM-URD, mismatched
unrelated donor; UR-CB, unrelated cord blood.
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melphalan > 140 mg/m2. Other regimens were classiﬁed as reduced-
intensity conditioning (RIC) [21].
Low-risk disease status included the following: ﬁrst and second complete
remission in acute leukemia and lymphoma, refractory anemia and refractory
anemia with ringed sideroblasts (myelodysplastic syndromes), and ﬁrst and
second chronic phase of chronic myeloid leukemia and nonmalignant disor-
ders. Other diseases were classiﬁed as high-risk disease status.
Overall survival (OS) was deﬁned as the number of days from allo-HSCT
until death from any cause. The incidence of relapse was deﬁned as the
number of days from allo-HSCT to relapse of the underlying disease. Non-
relapse mortality (NRM) was deﬁned as the number of days from allo-HSCT
to death without relapse. Any patient who was alive at the last follow-up
date was censored.
Neutrophil engraftment was deﬁned as the continuous achievement of
neutrophil counts of 500  106/L or higher. Platelet recovery was deﬁned as
continuous achievement of platelet counts of 20  109/L or higher without
transfusion.
In univariate analysis, the effect of HHV-6 reactivation on outcomes was
analyzed using landmark methods. OS and NRM were analyzed among
patients who survived more than 30 days after transplantation and relapse
was analyzed among those who survivedwithout relapsemore than 30 days
after transplantation. In multivariate analysis, the impact of HHV-6 reac-
tivation on other outcomes was studied as a time-dependent variable. OS,
NRM, acute GVHD, and hematopoietic recovery were analyzed in all pa-
tients; chronic GVHD was analyzed in patients who survived more than
100 days after transplantation.
The Fisher’s exact test and the Mann-Whitney test were used for com-
parison of categorical and continuous variables, respectively. OS was esti-
mated by the Kaplan-Meier method and was compared using a log-rank test.
Relapse and NRMwere considered competing risk events for each other and
were compared using Gray’s test. The cumulative neutrophil and platelet
recoveries and incidences of grades 2 to 4 acute GVHD and chronic GVHD
were also estimated and compared by Gray’s test considering death without
these events as a competing risk. In a multivariate analysis, the Cox propor-
tional hazard model was used for all events and the clinical impact of HHV-6
reactivation on other outcomes was always studied as a time-dependent
variable. The clinical impact of HHV-6 was adjusted for variables with a P
value of less than .20 in a univariate analysis. The following variables were
compared by univariate analysis: age at allo-HSCT, sex, primary disease,
disease risk, conditioning regimen, and donor source. P values were 2-sided
and differences were considered to be statistically signiﬁcant when P < .05.
All statistical analyses were performed using EZR (R version 2.13.0) [22].RESULTS
Patient Characteristics
Table 1 shows patients’ characteristics. Of 236 patients,
138 (58.5%) developed HHV-6 reactivation (reactivation
group) and 98 (41.5%) did not (control group). The median
maximum DNA level was 326.5 copies/mL (range, <125 to
290,000) in the reactivation group. Of the 3 patients who
received conditioning containing antithymocyte globulin, 1
(33.3%) developed HHV-6 reactivation. Age at allo-HSCT, sex,
background disease, and conditioning regimen were com-
parable in both groups. The proportion of patients with high-
risk disease tended to be higher in the reactivation group
(P¼ .08). A higher number in the reactivation group received
HLA-mismatched and cord blood transplantations compared
with the control group (P < .001).OS
The probability of OS of the reactivation group was
signiﬁcantly lower than that of the control group (45.7%
versus 59.7%, respectively, at 3 years; P¼ .003) (Figure 1A). In
subgroup analysis stratiﬁed according to conditioning in-
tensity, the negative impact of HHV-6 reactivation was seen
in the MAC group (42.1% for reactivation group versus 59.0%
for control group at 3 years, P ¼ .008) (Figure 2A). In contrast
with univariate analysis, multivariate analysis of all patients
indicated HHV-6 reactivation had no signiﬁcant impact on
OS after adjusted covariates (Table 2). On the other hand,
multivariate analysis of subgroups stratiﬁed by conditioningintensity revealed that HHV-6 reactivation was a risk factor
for worse OS with borderline signiﬁcance in the MAC group
(hazard ratio [HR], 1.62; 95% conﬁdence interval [CI], .97 to
2.73; P ¼ .07) (Table 2).
Relapse
The cumulative incidences of relapse were similar be-
tween both groups (29.0% for reactivation group versus
30.7% for control group at 3 years, P ¼ .97) (Figure 1B).
Similarly, HHV-6 reactivation did not affect relapse in sub-
group analysis stratiﬁed according to conditioning intensity
(Figure 2C,D). In multivariate analysis, HHV-6 reactivation
had no signiﬁcant effect on the relapse rate after adjusting
for covariates (Table 2).
NRM
The cumulative incidence of NRM in the reactivation
group was signiﬁcantly higher compared with the control
group (27.7% for reactivation group versus 13.7% for control
group at 3 years, P ¼ .003) (Figure 1C). In subgroup analysis
stratiﬁed by conditioning intensity, the cumulative incidence
of NRM in the reactivation group was signiﬁcantly higher in
the MAC group (29.8% for reactivation group versus 13.3% for
control group at 3 years, P ¼ .01) and tended to be higher in
the RIC group (22.4% for reactivation group versus 12.6% for
control group at 3 years, P ¼ .08) (Figure 2E,F). Multivariate
analysis of all patients showed that risk of NRMwas higher in
the reactivation group compared with in the control group
(HR, 2.73; 95% CI, 1.31 to 5.68; P ¼ .007) (Table 2). In multi-
variate analysis of subgroups stratiﬁed by conditioning
intensity, HHV-6 reactivation had an adverse impact on
the NRM in the MAC group (HR, 3.04; 95% CI, 1.31 to 7.04;
P ¼ .009). HHV-6 reactivation affected NRM with borderline
signiﬁcance in the RIC group (HR, 2.88; 95% CI, .94 to 8.77;
P ¼ .06) (Table 2).
Hematopoietic Recovery and Incidence of Acute GVHD
Multivariate analysis of all patients indicated that HHV-6
reactivationwas associated with a higher incidence of grades
Figure 1. Landmark analysis of all patients 30 days after transplantation. (A) OS with or without HHV-6 reactivation. (B) Relapse with or without HHV-6 reactivation.
(C) NRM with or without HHV-6 reactivation.
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Multivariate analysis of subgroups stratiﬁed by conditioning
intensity suggested HHV-6 was associated with a higher
incidence of grades 2 to 4 acute GVHD in the MAC group (HR,
2.09; 95% CI, 1.12 to 3.88; P ¼ .02). In contrast, HHV-6 reac-
tivation had no signiﬁcant impact on the incidence of grades
2 to 4 acute GVHD in the RIC group (HR, .98; 95% CI, .38 to
2.51; P ¼ .97) (Table 2).
In multivariate analysis, HHV-6 reactivation did not
signiﬁcantly affect neutrophil recovery and platelet recovery
(Table 2).
CMV Reactivation
Multivariate analysis of all patients showed that HHV-6
reactivation was signiﬁcantly correlated with a higher
incidence of CMV reactivation (HR, 2.24; 95% CI, 1.47 to
3.41; P < .001) (Table 2). Similarly, multivariate analysis of
subgroups stratiﬁed by conditioning intensity indicated
that HHV-6 reactivation was associated with a higher
incidence of CMV reactivation in the RIC group (HR, 2.05;
95% CI, 1.11 to 3.80; P ¼ .02). HHV-6 reactivation wasassociated with higher incidence of CMV reactivation with
borderline signiﬁcance in the MAC group (HR, 1.68; 95% CI,
.99 to 2.83; P ¼ .05).
Causes of NRM
Forty of 138 reactivation group patients and 11 of 98
control group patients died of NRM. There was no signiﬁ-
cant difference in the incidence of fatal acute GVHD
between both groups (12.5% for reactivation group versus
27.3% for control group, P ¼ .35). The incidence of fatal
idiopathic interstitial pneumonia in the control group was
signiﬁcantly higher than that in the reactivation group
(7.5% for reactivation group versus 36.4% for control group,
P ¼ .03).
HHV-6 Encephalitis
HHV-6 encephalitis developed in 12 patients. The
maximum HHV-6 DNA level of patients developing HHV-6
encephalitis was higher (2510 copies/mL [range, <125 to
18,300]) than that of patients who did not developed en-
cephalitis (302.5 copies/mL [range,<125 to 290,000], P¼ .02).
Figure 2. Landmark analysis of patients grouped according to conditioning intensity 30 days after transplantation. (A) OS with or without HHV-6 reactivation in MAC
group. (B) OS with or without HHV-6 reactivation in RIC group. (C) Relapse with or without HHV-6 reactivation in MAC group. (D) Relapse with or without HHV-6
reactivation in RIC group. (E) NRM with or without HHV-6 reactivation in MAC group, and (F) NRM with or without HHV-6 reactivation in RIC group.
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Allo-HSCT recipients are at high risk of developing a
reactivation within the ﬁrst 4 weeks after transplantation
[23]. Therefore, we performed HHV-6 DNA monitoring
weekly until 4 weeks after transplantation, as described in
previous reports [19,24,25].
The current study revealed that HHV-6 reactivation was
associated with higher incidences of acute GVHD, CMV
reactivation, and NRM. Notably, subgroup analysis stratiﬁed
according to conditioning intensity indicated that the sig-
niﬁcant impact of HHV-6 reactivation on acute GVHD was
observed only in the MAC group. Although HHV-6 reac-
tivation had no signiﬁcant impact on OS in the whole cohort,
worse OS was noted in MAC group. The negative impact of
HHV-6 reactivation on transplantation outcomes was
stronger in the MAC group compared with in the RIC group.
To the best our knowledge, this is the ﬁrst report to show that
the impact of HHV-6 reactivation differed according to in-
tensity of conditioning.
In the current study, donor source and HLA mismatch
were associated with HHV-6 reactivation, as reportedTable 2
Impact of HHV-6 Reactivation on Outcomes of Transplantation, by Multivariate An
Outcome All Patients MAC
HR 95% CI P Value HR
OS 1.43 .91-2.24 .13 1.62
Relapse .96 .58-1.58 .87 1.00
NRM 2.73 1.31-5.68 .007 3.04
Neutrophil engraftment 1.25 .89-1.71 .19 1.48
Platelet engraftment .84 .60-1.18 .32 .79
Acute GVHD (II-IV) 1.87 1.13-3.09 .01 2.09
Chronic GVHD 1.46 .91-2.33 .12 1.36
CMV antigenemia 2.24 1.47-3.41 <.001 1.68previously [14,17,26]. Dulery et al. suggested that MAC was a
risk factor for HHV-6 reactivation [19]. However, we found no
such association in the current study.
Several studies reported an association between a high
level of HHV-6 DNA and complications. Betts et al. re-
ported that high-level culture-negative pneumonitis was
frequent in patients with a high level of HHV-6 DNA [27].
Ogata et al. indicated that a high level of HHV-6 DNA was
associated with encephalitis [11]. Similarly, plasma HHV-6
DNA level of patients who developed HHV-6 encephalitis
was higher than that of patients who did not developed
encephalitis.
Whether there is a causal association between HHV-6
reactivation and incidence of acute GVHD remains contro-
versial. However, recent large cohort studies indicated sig-
niﬁcant associations between HHV-6 reactivation and acute
GVHD [16,19]. It has been suggested that tissue damage
caused by conditioning and previous therapy triggers
development of acute GVHD [28,29]. HHV-6 infection causes
tissue damage by triggering the inﬂammatory response and
may play a role in the development of acute GVHD [30]. Inalysis
RIC
95% CI P Value HR 95% CI P Value
.97-2.73 .07 1.35 .61-2.99 .46
.52-1.91 1.00 .94 .42-2.10 .88
1.31-7.04 .009 2.88 .94-8.77 .06
.96-2.26 .07 1.03 .59-1.81 .91
.51-1.25 .32 .90 .51-1.57 .71
1.12-3.88 .02 .98 .38-2.51 .97
.74-2.50 .32 1.56 .63-3.83 .34
.99-2.83 .05 2.05 1.11-3.80 .02
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the risk of acute GVHD. Furthermore, the current study in-
dicates that HHV-6 reactivation was associated with acute
GVHD only in the MAC group. This adverse impact of HHV-6
reactivation on the incidence of acute GVHD was not
observed in the RIC group. Perez-Simon et al. suggested that
the intensity of the conditioning regimen inﬂuences devel-
opment of GVHD [31]. The causal association between HHV-
6 reactivation and acute GVHD may be explained by the
severity of the conditioning intensity, as RIC regimens
decrease the incidence of acute GVHD through reduced tis-
sue damage.
Several studies have indicated that HHV-6 reactivation
increases the risk of subsequent CMV reactivation [7,16].
Likewise, the current study indicates that HHV-6 reactivation
was associated with a higher incidence of CMV reactivation.
A difference by conditioning intensity was not observed for
the association between HHV-6 reactivation and the inci-
dence of CMV reactivation.
We deﬁned HHV-6 reactivation as any detection of HHV-6
DNA, at any level, as described in previous studies
[11,15,16,19]. Previous studies using other deﬁnitions have
also reported that HHV-6 reactivation was associated with
development acute GVHD [20,25].
This analysis has some limitations, including its single-
center, retrospective design. The number of patients stud-
ied may not be large enough to accurately detect a deﬁnitive
effect of HHV-6 reactivation. However, most patients in our
cohort received uniform conditioning regimens. Since 2008,
preemptive therapy was started when HHV-6 DNA exceeded
125 copies/mL to prevent encephalitis. However, previous
trials suggested HHV-6 DNA-guided preemptive therapy was
inadequate in preventing HHV-6 encephalitis [24,32,33].
Further studies are needed to prove efﬁcacy of preemptive
therapy of HHV-6 encephalitis.
In conclusion, the current study indicates that HHV-6
reactivation is associated with poor outcomes of allo-
HSCT. The adverse impact of HHV-6 reactivation on the
incidence of acute GVHD and NRM was prominent in the
MAC group. Accordingly, we may have to pay more atten-
tion to HHV-6 reactivation, especially in the setting of
MAC.
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